Published in Vaccine Weekly, June 12th, 2002
Revenues for the quarter ended March 31, 2002 were $628,000 compared with $2.0 million for the same period last year. Revenue for the current quarter was primarily attributable to the commencement of activities under the company's new $10.2 million collaboration with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly